• Profound Medical forecast preliminary Q3 2026 revenue of USD 9.8 million to USD 10.0 million, above Wall Street expectations.
• Implies 85% to 89% growth from Q3 2025 revenue of USD 5.3 million.
• Implies 292% to 300% sequential growth from Q2 2026 revenue of USD 2.5 million.
• Revenue expected 45% to 47% above Bloomberg mean consensus of USD 6.78 million.
• Q3 gross margin expected to exceed 70%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profound Medical Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610071615PRIMZONEFULLFEED9841699) on October 07, 2026, and is solely responsible for the information contained therein.